Dapagliflozin reduces risk of hospitalization in adults with chronic kidney disease
December 05, 2022 2 minute read Source/Disclosures Disclosures: Schechter reports that the study was funded by AstraZeneca. He also reports receiving travel assistance from Novo Nordisk. Please see the study for relevant financial information from all other authors. ADD A SUBJECT TO EMAIL ALERTS Receive an email when new articles are published on Please provide …
Dapagliflozin reduces risk of hospitalization in adults with chronic kidney disease Read More »